HilleVax, Inc. (HLVX)
$12.96
-0.14 (-1.07%)
Rating:
Recommendation:
-
| Symbol | HLVX |
|---|---|
| Price | $12.96 |
| Beta | 0.000 |
| Volume Avg. | 0.06M |
| Market Cap | 627.483M |
| Shares () | - |
| 52 Week Range | 11.35-23.1 |
| 1y Target Est | - |
| DCF Unlevered | HLVX DCF -> | |
|---|---|---|
| DCF Levered | HLVX LDCF -> | |
| ROE | -34.13% | Strong Sell |
| ROA | -30.26% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.37% | Neutral |
| P/E | -324 | Strong Sell |
| P/B | 2.25 | Strong Buy |
Latest HLVX news
About
Download (Excel)Dr. Robert M. Hershberg M.D., Ph.D.
Healthcare
Biotechnology
NASDAQ Global Select
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.